While the ERα affinity for G15 is quite low (>10 mM), an improved GPER antagonist, named G36, was developed by the same investigators with still lower affinity for ERα, and the ability to block the growth of transplanted ER-negative type II endometrial cancer cells [65]. This evidence concerns the gene ESR1 and endometrial cancer.